Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin)

• Catalog Number: orb1805476
• Category: Antibodies
• Description: Anti-HGFR / c-Met Reference Antibodydy and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.
• Clonality: Monoclonal
• Tested applications: ELISA, FA, FACS, Kinetics
• Reactivity: Human
• Isotype: IgG
• Purity: > 95%
• Conjugation: Unconjugated
• MW: 145.64 kDa
• Target: HGFR / c-Met
• Endotoxins: < 1 EU/mg
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: 100 mM Pro-Ac 20 mM Arg pH 5.0
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin)is more than 95% ;determined by SEC-HPLC.

Immobilized human cMet His at 2 μg/mL can bind Anti-HGFR / c-Met Reference Antibody (telisotuzumab vedotin);EC50=0.105μg/mL.